Authors
Loading...
Randomized trial demonstrates enhanced antitumor effects in cancer models using SOS1 inhibitors combined with KRAS inhibitors, suggesting a new therapeutic strategy.
Bagal et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: